Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology

Södertälje, Sweden, & San Francisco, USA and Kyoto, Japan, 30 May 2024 – Anocca AB  (Anocca), a leading T-cell receptor-engineered T-cell (TCR-T) therapeutics company, and Shinobi Therapeutics (Shinobi), developer of immune-evasive induced pluripotent stem cell (iPSC)-derived CD8 αβT-cell therapies (iPS-T), today announced a strategic partnership to use Shinobi’s proprietary immune evasive iPS-T cell platform with novel candidate TCRs, discovered and validated by Anocca, to develop a new class of off-the-shelf allogeneic TCR engineered iPS-T-cell therapies (TCR-iPS-T)